Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07248228 · ClinicalTrials.gov registry record · Phase 2
Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07248228: Recruiting Phase 2 study, sponsored by Case Comprehensive Cancer Center.
NCT07248228 is a Phase 2 study that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07248228, a Phase 2 study, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.
Primary Outcome
Time to NCF is defined as cognitive decline on the reliable change index (RCI) on at least one of the following tests: HVLT-R, TMT A/B, COWAT, BVMT-R. Tests are defined below.
Interventions
- DRUG Memantine
- RADIATION MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT))
- RADIATION HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT))
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
What NCT07248228 shows while recruiting
NCT07248228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which Memantine is the first listed.
NCT07248228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07248228 about?
NCT07248228 is a clinical study titled "Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)". Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve ...
What is the current status of trial NCT07248228?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-07. Estimated completion is 2028-11.
What interventions are being tested in trial NCT07248228?
The interventions under investigation include: Memantine (DRUG), MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT)) (RADIATION), HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT)) (RADIATION).
Who is sponsoring clinical trial NCT07248228?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07248228's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia